Clinical trials: Artery Disease
Hypotension
Hypotension Prediction Index Study (HPI Study)
A prospective, single-arm, open-label, multicenter post-approval study to determine whether the use of the Acumen HPI Software to guide intraoperative hemodynamic management in non-cardiac surgery reduces the duration of…
- Trial name
- NCT03805217
- Testing
- EV1000A Clinical Platform with Acumen Hypotension Prediction Index Feature Software
- Where
- 11 sites in United States
- Volunteers
- 485 people
- Sponsor
- Edwards Lifesciences
Peripheral Vascular Diseases, Coronary Artery Disease
Single Arm, Prospective, Open-label, Multi-center Clinical Investigation for the Demax Guide Wire
The objectives of this study are to confirm the safety and performance of the Guide Wire when used in patients with peripheral vascular or coronary vascular disease for diagnostic or treatment procedures and will be the pivotal…
- Trial name
- SPOMCIDGW (NCT06735846)
- Testing
- Guide wire
- Volunteers
- 100 people
- Sponsor
- DemaxGroup
Diabetes, Peripheral Arterial Disease
DLBS1033 Treatment in Diabetic With Peripheral Arterial Disease
This is a prospective, randomized, double-blind, double-dummy, and controlled study of DLBS1033 for the improvement of ankle-brachial index in diabetic patients with peripheral arterial disease (PAD).
- Trial name
- NCT02145988
- Testing
- DLBS1033
- Where
- 2 sites in Indonesia
- Volunteers
- 11 people
- Sponsor
- Dexa Medica Group
Coronary Atherosclerosis
Bifurcation Lesion Analysis and STenting / BLAST
The purpose of this research study is to determine if Intravascular Ultrasound (IVUS) grayscale and VH (Virtual Histology)-IVUS pre-stenting can assess more accurately the location, amount, and type of a blockage than angiogram…
- Trial name
- BLAST (NCT02316782)
- Testing
- Blinded IVUS assessment, Nonblinded IVUS
- Where
- 10 sites in United States, Denmark and 6 more
- Volunteers
- 195 people
- Sponsor
- Volcano Corporation
Angina Pectoris, Coronary Heart Disease
Evaluate the Efficacy and Safety of MUSK Pill on Coronary Microvascular Dysfunction
Objective to evaluate the effect of Shexiang Baoxin Pill on myocardial ischemia in patients with coronary microvascular dysfunction (non obstructive coronary heart disease) through a randomized, double-blind, placebo-controlled…
- Conditions
- Angina Pectoris, Coronary Heart Disease, X Syndrome, Angina, Non Obstructive Coronary Artery Disease
- Trial name
- NCT04984954
- Testing
- MUSK pill
- Where
- China
- Volunteers
- 264 people
- Sponsor
- Shanghai Hutchison Pharmaceuticals Limited
Pulmonary Arterial Hypertension
Long-Term, Open Label Extension Study of Pemziviptadil (PB1046) in PAH Subjects Following Completion of Study PB1046-PT-CL-0004
This is a multi-center, Phase 2 Long-Term, Open Label Extension (OLE) Study to assess the safety and tolerability of pemziviptadil (PB1046) at an optimally titrated dose.
- Trial name
- VIP Extend (NCT03795428)
- Testing
- Pemziviptadil (PB1046) Injection
- Where
- 16 sites in United States
- Volunteers
- 25 people
- Sponsor
- PhaseBio Pharmaceuticals Inc.
Peripheral Artery Disease, Femoropopliteal Artery Disease
First-in-man Evaluation of a Novel, Microcrystalline Paclitaxel Coated Balloon for Treatment of Femoropopliteal Artery Disease (PAX-r)
The purpose of this pivotal, first in man study will be to evaluate safety and efficacy of the novel, microcrystalline paclitaxel coated balloon (mcPCB, PAK, Balton) in the treatment of femoropopliteal artery disease.
- Trial name
- PAX (NCT02145065)
- Testing
- Local drug delivery via microcrystalline paclitaxel balloon coating (PAK,Balton, Poland), Plain balloon angioplasty, uncoated balloon (Neptun, Balton, Poland)
- Where
- Poland
- Volunteers
- 66 people
- Sponsor
- Balton Sp.zo.o.
Peripheral Arterial Occlusive Disease
Safety and Tolerability of NV1FGF in Patients With Severe Peripheral Artery Occlusive Disease
The primary objective is to evaluate safety and tolerability of single and repeated administrations of escalating doses of NV1FGF administered intramuscularly in patients with severe Peripheral Artery Occlusive Disease (PAOD)…
- Trial name
- NCT01157156
- Testing
- XRP0038 (NV1FGF)
- Where
- 2 sites in United States, Finland
- Volunteers
- 51 people
- Sponsor
- Sanofi
Hypertension, Pulmonary
Riociguat Clinical Effects Studied in Patients With Insufficient Treatment Response to Phosphodiesterase-5 Inhibitor
BAY63-2521 Riociguat leads to the relaxation of smooth muscle cells in pulmonary arteria and may also inhibit abnormal remodeling of lung blood vessels.
- Trial name
- RESPITE (NCT02007629)
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 27 sites in United States, Belgium and 7 more
- Volunteers
- 61 people
- Sponsor
- Bayer
Osteoarthritis
Transcatheter Arterial Micro-Embolization (TAME) Using Nexsphere-F in Patients With Knee Degenerative Osteoarthritis
Among knee degenerative osteoarthritis patients aged 50 or older, it will prove the therapeutic effect and safety of Nexsphere-F embolization for patients who need additional treatment because pain is not controlled even if…
- Trial name
- NCT05917028
- Testing
- Transcatheter Arterial Micro-Embolization
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Next Biomedical Co., Ltd.
Coronary Artery Disease
Evaluation of a Thin Strut Metallic Stent: the Elixir DynamX Clinical Study
The DynamX (Bioadaptor) study is a prospective, consecutive enrollment study designed to enroll up to 50 patients requiring treatment of a single, de novo lesion ≤ 24 mm in length located in a vessel ≥ 2.5 mm and ≤ 3.5 mm in…
- Trial name
- NCT03429894
- Testing
- Percutaneous Coronary Intervention
- Where
- 2 sites in Belgium, Italy
- Volunteers
- 50 people
- Sponsor
- Elixir Medical Corporation
Arterial Hypertension, Albuminuria
Effects of Linagliptin on Endothelial- , Renal-, and Retinal Function in Patients With Hypertension and Albuminuria
A recent study with the DPP-IV inhibitor Linagliptin showed an improvement in the urinary albumin creatinine ratio in patients with diabetic nephropathy. Gutzwiller et. Al.
- Trial name
- NCT02376075
- Testing
- Linagliptin
- Where
- Germany
- Volunteers
- 43 people
- Sponsor
- ikfe-CRO GmbH
Critical Limb Ischemia, Chronic Limb-Threatening Ischemia
PROMISE I Early Feasibility Trial of the LimFlow Stent Graft System
This pilot study will investigate the safety, effectiveness and feasibility of the LimFlow Stent Graft System for creating an AV fistula in the Below The Knee (BTK) vascular system using an endovascular, minimally invasive…
- Trial name
- NCT03124875
- Testing
- LimFlow System
- Where
- 7 sites in United States
- Volunteers
- 32 people
- Sponsor
- LimFlow, Inc.
Intracranial Embolism, Cerebral Thromboembolism
Effect of ARC1779 on Cerebral Microembolism in Patients Undergoing Carotid Endarterectomy
The purpose of this study is to determine, in patients undergoing carotid endarterectomy, the effect of ARC1779 Injection on the number of microembolic signals detected by transcranial Doppler immediately after surgery.
- Conditions
- Intracranial Embolism, Cerebral Thromboembolism, Carotid Stenosis
- Trial name
- NCT00742612
- Testing
- ARC1779 Injection
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 100 people
- Sponsor
- Archemix Corp.
Venous Ulcer, Arterial Ulcer
PluroGel on Wounds of Mixed Etiology
A randomized controlled study (RCT) to investigate the topical effectiveness of PluroGel in healing venous and mixed aetiology leg ulcers.
- Trial name
- NCT03275831
- Testing
- PluroGel, Intrasite gel
- Where
- 2 sites in United Kingdom
- Volunteers
- 16 people
- Sponsor
- Medline Industries
Renal Artery Stenosis
Comparison of Best Medical Treatment Versus Best Medical Treatment Plus Renal Artery Stenting
The clinical investigation is a prospective, international, multi-centre, randomized (1:1) trial with follow ups at 2, 6, 12 months and 3 years.
- Trial name
- RADAR (NCT00640406)
- Testing
- Dynamic Renal Stent plus Best Medical Treatment, Best Medical Treatment
- Where
- Germany
- Volunteers
- 86 people
- Sponsor
- Biotronik AG
Hypertension, Pulmonary
Examination of Ventavis (Iloprost) Inhalation Behavior Using the I-Neb AAD System in Patients With Pulmonary Arterial Hypertension When Switching the Iloprost Nebulizer Solution for Inhalation From 10 μg/mL (V10) to 20 μg/mL (V20)
The aim of this study is to examine inhalation behavior in patients enrolled in the German Ventavis patient support program Ventaplus when these patients are switched from Ventavis (Iloprost) 10 μg/mL to Ventavis (Iloprost) 20…
- Trial name
- VENTASWITCH (NCT02826252)
- Testing
- Iloprost,(Ventavis, BAYQ6256), I-Neb AAD system
- Where
- Germany
- Volunteers
- 64 people
- Sponsor
- Bayer
Angioplasty, Cardiovascular Disease
XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS) China Single-Arm Study
Abbott Vascular (AV) obtained marketing approval for the XIENCE PRIME Everolimus Eluting Coronary Stent System (XIENCE PRIME EECSS) in China from the China Food and Drug Administration (CFDA) on August 10th, 2011.
- Conditions
- Angioplasty, Cardiovascular Disease, Coronary Artery Disease, Coronary Heart Disease
- Trial name
- XP China SAS (NCT01894152)
- Testing
- XIENCE PRIME Everolimus Eluting Coronary Stent System (EECSS)
- Where
- United States
- Volunteers
- 2,002 people
- Sponsor
- Abbott Medical Devices
Coronary Artery Disease
A Study of Hemopure® to Enhance Tissue Preservation During Cardiopulmonary Bypass Surgery
The purpose of this study is to determine if Hemopure® will enhance tissue preservation during Cardiopulmonary Bypass surgery.
- Trial name
- NCT00301535
- Testing
- HBOC-201 (hemoglobin glutamer-250 bovine)
- Where
- 3 sites in Greece, South Africa and 1 more
- Volunteers
- 60 people
- Sponsor
- Biopure Corporation
Coronary Artery Disease, Percutaneous Coronary Intervention
The Efficacy, Safety and Pharmacokinetic of Antiplatelet Therapy for Vicagrel
This is a multi-center, randomized, double-blind, triple-dummy, parallel-controled, dose-exploration phase II trial. Patients with coronary atherosclerotic heart disease and planned percutaneous coronary intervention （PCI） will…
- Conditions
- Coronary Artery Disease, Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors
- Trial name
- NCT03599284
- Testing
- Vicagrel 5mg, Vicagrel 6mg, Vicagrel 7.5mg
- Where
- 27 sites in China
- Volunteers
- 279 people
- Sponsor
- Jiangsu vcare pharmaceutical technology co., LTD
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.